Journal for ImmunoTherapy of Cancer (Nov 2020)
77 Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC)
Abstract
No abstracts available.